- Home
- ANVS vs ANL Comparison
ANVS vs ANL Comparison
Compare ANVS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANVS | ANL |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 350.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ANVS | ANL |
|---|---|---|
| Price | $2.49 | $9.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $13.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 313.1K | 208.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.88 |
| 52 Week High | $5.50 | $12.09 |
Technical Indicators
Market Signals| Indicator | ANVS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 55.38 |
| Support Level | $2.27 | $1.37 |
| Resistance Level | $2.63 | $10.15 |
| Average True Range (ATR) | 0.20 | 0.97 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 21.54 | 56.12 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.